Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes.
about
Cytochrome P450 1A2 (CYP1A2) activity, mammographic density, and oxidative stress: a cross-sectional studyApplications of CYP450 testing in the clinical settingClinical use of pharmacogenomic tests in 2009Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional studySimultaneous measurement of in vivo P-glycoprotein and cytochrome P450 3A activitiesScreening of Genetic Polymorphisms of CYP3A4 and CYP3A5 Genes.Phase I trial of vinflunine and pemetrexed in refractory solid tumors.Evaluation of CYP3A activity in humans using three different parameters based on endogenous cortisol metabolism.Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy AdultsOntogeny of midazolam glucuronidation in preterm infants.Pharmacogenetic testing revisited: 5' nuclease real-time polymerase chain reaction test panels for genotyping CYP2D6 and CYP2C19.A highly sensitive liquid chromatography tandem mass spectrometry method for simultaneous quantification of midazolam, 1'-hydroxymidazolam and 4-hydroxymidazolam in human plasma.Variability in drug metabolizing enzyme activity in HIV-infected patients.Prediction of relative in vivo metabolite exposure from in vitro data using two model drugs: dextromethorphan and omeprazole.Rationalization and prediction of in vivo metabolite exposures: the role of metabolite kinetics, clearance predictions and in vitro parameters.Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots.The influence of sex, ethnicity, and CYP2B6 genotype on bupropion metabolism as an index of hepatic CYP2B6 activity in humans.Effect of single and repeat doses of casopitant on the pharmacokinetics of CYP450 3A4 substrates midazolam and nifedipineMidazolam pharmacokinetics in morbidly obese patients following semi-simultaneous oral and intravenous administration: a comparison with healthy volunteers.Human CYPs: in vivo and clinical aspects.Limited sampling strategy of partial area under the concentration-time curves to estimate midazolam systemic clearance for cytochrome P450 3A phenotyping.Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation.Interactions of herbs with cytochrome P450.An enhanced in vivo stable isotope labeling by amino acids in cell culture (SILAC) model for quantification of drug metabolism enzymes.How useful is the "cocktail approach" for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo?Cardiac arrest and therapeutic hypothermia decrease isoform-specific cytochrome P450 drug metabolism.Cytochrome P450 enzyme mediated herbal drug interactions (Part 1)Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo bilobaAssessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin.Phenotyping CYP3A using midazolam in cancer and noncancer Asian patientsEffects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity.Pharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1.Dexamethasone as a probe for vinorelbine clearance.Effect of widely used combinations of antiretroviral therapy on liver CYP3A4 activity in HIV-infected patients.Poor correlation between 6beta-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activityThe effect of St John's wort extracts on CYP3A: a systematic review of prospective clinical trials.Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence.Food-drug interactions via human cytochrome P450 3A (CYP3A).Dose-response of berberine on hepatic cytochromes P450 mRNA expression and activities in mice4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes.
P2860
Q21195169-BD5168D8-8379-4D26-A111-2E43FF2008FBQ24621760-6AD727D7-79FC-46BA-ADE6-EDFA9068FD28Q24657536-77CEDA7C-A1B6-4FC8-8027-853E6B59DE9FQ24806052-47893BC2-EC5D-42A1-8887-0EF718E57FB7Q28269209-682DA1C3-4165-4F3E-951F-D96DDAEDA28DQ30357429-3D9F13E6-7E1E-42F9-B7D9-FD8768ACF8BFQ30428531-8704B5D9-B716-4B60-B85A-53071DE5E497Q33555015-77FBE8BD-CDAA-49F7-AE97-67994B819B07Q33571585-1FB531AB-CACF-46AB-96ED-2C824CD11262Q33587843-E63E0931-EFF0-4BEE-ADBD-92436850F1A4Q33597438-93B1B76A-BE13-4748-A485-D5ABFB643222Q33785079-748BFF66-ED96-47E2-BB18-F0FC6C7AD63EQ33791508-560ED675-F213-4D7E-8B70-D2429E5CF0E1Q34051253-D9AF61EC-8091-4C6D-8E85-2BE5C5D4F877Q34071827-E9C742EF-1DD4-4472-BB0E-39AFDF3F8E8CQ34116690-6266AF30-5C0E-4527-B980-75E8CDCD7BE5Q34169785-BB0B8B74-AD30-474E-9D3D-13F5BD2D8FD7Q34180470-A032E264-AA3F-45E8-AC61-1B5D7CE87EBAQ34227492-BF564406-2E4F-4057-B429-DCEFD24B53A6Q34627903-1C34D471-9C43-49CF-A18C-1FFA6E27BDE4Q34810573-3EB4892D-B898-4A26-B428-2A63653ACD14Q35027930-DE5904CA-7072-429E-A4E2-BEA44FB772D8Q35085032-15ADD7D5-A029-48D7-9226-CE4AC44A19DCQ35148413-22F96EFF-14CD-4EAA-A032-4EE84645A739Q35149421-069D72EA-166D-4AF5-BB8F-6C41F35DFED0Q35579550-3C37647B-BF61-4D8D-972B-E923AC7CDD84Q35725540-93D382E5-3B54-49C0-B470-FE9884C1EC8CQ35765836-2E32FE30-11FE-4970-BD9A-3CC9BA542148Q35781985-FDBD1947-A430-4FAF-A876-C98915CE238EQ35825212-A35A58E6-0F05-4EEF-A260-FE08222FA2BEQ35825510-A90DB9F7-4979-4A7E-B8B8-50D256C5CDD7Q35825950-21235785-E065-4291-93B2-263105EB951CQ35827137-F5837564-BFF0-4AD7-831E-B8CE223B4E8EQ35827661-54AA1FA5-9A2E-4DE4-86E7-47C2D5904660Q35827674-64F5B325-7664-4AE8-9EA8-01AE1618F74CQ35827865-21425D17-6622-4998-A823-EC1E24445AC2Q35884179-5C20AEC4-05AE-48F8-A192-B2F8D77F2286Q36016526-B7D66639-8BE2-4B49-92E3-56F5E7702905Q36062928-F52C1472-9965-4E9B-A06A-248F8B6507F5Q36072512-7EB2A899-2D43-425C-91D8-EC4F12209D91
P2860
Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes.
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Phenotyping of drug-metabolizi ...... hrome P450 phenotyping probes.
@ast
Phenotyping of drug-metabolizi ...... hrome P450 phenotyping probes.
@en
type
label
Phenotyping of drug-metabolizi ...... hrome P450 phenotyping probes.
@ast
Phenotyping of drug-metabolizi ...... hrome P450 phenotyping probes.
@en
prefLabel
Phenotyping of drug-metabolizi ...... hrome P450 phenotyping probes.
@ast
Phenotyping of drug-metabolizi ...... hrome P450 phenotyping probes.
@en
P2093
P1476
Phenotyping of drug-metabolizi ...... hrome P450 phenotyping probes.
@en
P2093
Bertino JS Jr
Nafziger AN
Streetman DS
P304
P356
10.1097/00008571-200004000-00001
P577
2000-04-01T00:00:00Z